• miR-146a/b-5p–IRAK1–NF-κB in URSA

  2026-09-23

  The study links reduced miR-146a/b-5p with increased IRAK1 and NF-κB signaling in unexplained recurrent spontaneous abortion (URSA), combining public-dataset analysis with trophoblast and mouse experiments. Its results support a regulatory model in which miR-146a/b-5p can influence trophoblast function and pregnancy outcomes, while leaving important questions about clinical validation and mechanism unresolved.

• MCC950 sodium for NLRP3 Research Workflows

  2026-09-23

  MCC950 sodium enables selective NLRP3 inflammasome inhibition across endothelial, macrophage, PBMC, and autoimmune disease workflows. This guide translates the reference study into practical assay design, controls, optimization strategies, and troubleshooting steps.

• Nonivamide: TRPV1 Assays Across Cancer and Immunity

  2026-09-22

  Nonivamide, a capsaicin analog and selective TRPV1 agonist, connects cancer-cell apoptosis research with emerging neuroimmune assay design. This guide explains how to separate direct cellular effects from TRPV1-driven somato-autonomic signaling while improving solubility, controls, and interpretation.

• Pyridostatin TFA: G-Quadruplex Assay Workflows

  2026-09-22

  Pyridostatin TFA provides a practical chemical perturbation strategy for stabilizing G-quadruplexes in telomere, cancer, and DNA secondary structure research. This guide connects cell-based dosing with the emerging RNA G-quadruplex–TDP-43 field while clearly separating validated product use from exploratory neurodegeneration applications.

• Intravesical p21 mRNA-LNP Therapy in Bladder Cancer

  2026-09-21

  This 2026 FASEB Journal study develops chemically modified p21 mRNA packaged in lipid nanoparticles for localized intravesical treatment of bladder cancer. The work links restoration of nuclear p21 to cell-cycle suppression, DNA-damage accumulation, apoptosis, and tumor control in an orthotopic mouse model, while also defining the delivery advantages and translational limitations of local mRNA therapy.

• Ertugliflozin: Translational Leverage Beyond Glycemia

  2026-09-21

  Ertugliflozin (PF-04971729) offers a selective way to interrogate renal glucose handling while opening a more nuanced translational conversation about cardioprotection, inflammation, and target-versus-drug effects. This article connects mechanism, model selection, dose interpretation, and experimental strategy for diabetes mellitus research and adjacent organ-protection studies.

• Exo1: A Temporal Map of Secretory Trafficking

  2026-09-20

  Exo1, or methyl 2-(4-fluorobenzamido)benzoate, enables time-resolved analysis of Golgi–ER traffic and exocytosis. This article explains how to use its distinctive ARF1-linked mechanism to separate intracellular secretion defects from tumor extracellular vesicle effects.

• Exo1 for Mechanism-Resolved Exocytosis Research

  2026-09-19

  Exo1, or methyl 2-(4-fluorobenzamido)benzoate, enables acute interrogation of Golgi–ER trafficking and exocytic output. This guide translates its ARF1-centered mechanism and recent tumor extracellular vesicle research into practical assay decisions without overstating translational evidence.

• Moxifloxacin: From Gyrase to Cell Phenotype

  2026-09-18

  Moxifloxacin is a fluoroquinolone antibiotic whose research value extends from bacterial DNA topology to mammalian-cell and metabolic endpoints. This guide presents a target-to-phenotype framework for interpreting gyrase assays, retinal ganglion-cell toxicity, and histamine-linked responses without conflating mechanistic evidence.

• Intravesical p21 mRNA-LNP Therapy in Bladder Cancer

  2026-09-18

  The reference study develops a localized, nonviral tumor suppressor replacement strategy by packaging chemically modified p21 mRNA in lipid nanoparticles for intravesical delivery. In cell and orthotopic mouse models, this approach restored p21 signaling, inhibited bladder tumor growth, and limited systemic exposure, while highlighting important formulation and translational questions.

• Paroxetine in Colon Cancer: MET and ERBB3

  2026-09-17

  The reference study shows that paroxetine suppresses colorectal cancer phenotypes in cell and xenograft models while implicating MET and ERBB3 signaling as a mechanistic axis. Its value is primarily preclinical: the work supports assay development and drug-repositioning research, but does not establish paroxetine as an oncology treatment.

• Mitoxantrone Workflows for ABCG2 Resistance Studies

  2026-09-17

  Build reproducible Mitoxantrone assays for DNA damage, apoptosis, and ABCG2-mediated drug resistance. This workflow combines practical dosing guidance with transporter-focused controls inspired by recent marein chemosensitization research.

• Exo1 for Mechanism-Resolved Exocytosis Assays

  2026-09-16

  Exo1 provides an acute way to dissect Golgi–ER membrane traffic, ARF1 behavior, and secretion without reproducing every effect of Brefeldin A. This guide translates its mechanism into practical exocytosis, membrane-trafficking, and extracellular-vesicle assay workflows while clearly separating established evidence from proposed applications.

• 2-NBDG Glucose Uptake Assay Kit for HCC

  2026-09-16

  Translate transporter-dependent glucose accumulation into a fast, non-radioactive metabolic readout for sorafenib-response studies. This workflow combines single-cell fluorescence, GLUT1 inhibition, viability gating, and lipid-metabolism phenotyping to distinguish metabolic adaptation from simple loss of cell number.

• Dye Models for Small Tissue Biopsies in Pathology

  2026-09-15

  The reference study evaluates whether visible dye marking can reduce the risk of losing or overlooking very small biopsy fragments during routine tissue processing. Merbromin, hematoxylin, and Alcian blue improved tissue visibility, but hematoxylin was favored because it combined visibility with lower toxicity and no reported interference during diagnostic slide review.

8162 records 1/545 page Next 12345 下5页 Last page